Molecular targets for the treatment of wounds, in particular chronic wounds

The present invention relates to a therapeutic compound comprising: an agent that inhibits the activity of at least one gene selected from the group consisting of MAF, MEOX2, SIX2 and homologues thereof having at least 50% identity with said genes and/or an agent that enhances the activity of at least one gene selected from the group consisting of CREB5, E2F1, EGR2, HIC1, IRF7, JUN, MYC, SRF, STAT4, TCF4, FOXS1, GLI1, SOX9 and homologues thereof having at least 50% identity with said gene for use in the treatment of wounds, preferably chronic wounds. 本发明涉及用于治疗伤口，优选慢性伤口的治疗性化合物，包含：-抑制至少个选自以下的基因的活性的试剂：MAF、MEOX2、SIX2及其与所述基因具有至少50％同性的同源物，和/或-增强至少个选自以下的基因的活性的试剂：CREB5、E2F1、EGR2、HIC1、IRF7、JUN、MYC、SRF、STAT4、TCF4、FOXS1、GLI1、SOX9及其与所述基因具有至少50％同性的同源物。